The Latest Breaking News from Centene

Centene Corporation (NYSE:CNC) has agreed to sell Magellan Rx to Prime Therapeutics LLC and PANTHERx Rare to a consortium of The Vistria Group, General Atlantic, and Nautic Partners.  Centene expects to receive approximately $2.8 billion in aggregate proceeds from the transactions. Magellan Rx is a comprehensive pharmacy solutions organization with specialty drug management, Medicaid administration, and comprehensive pharmacy…

US stock futures traded higher ahead of the much-awaited interest rate decision from the Federal Reserve. Investors, meanwhile, focused on some notable insider trades.

Over the past 3 months, 9 analysts have published their opinion on Centene (NYSE:CNC) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Centene Corporation (NYSE: CNC) has reported Q4 adjusted EPS of $1.01,

  Centene (NYSE:CNC) reported its Q4 earnings results on Tuesday, February 8, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

NHS England faces a legal challenge against a decision to approve a 'change in control' of primary care provider AT Medics

Judicial review hearing could overturn Centene takeover branded by opponents as ‘NHS privatisation by stealth’

French CAC 40 Index gained around 1% this morning, partially recovering from previous session’s 4% plunge, as investors await the policy decision from the Federal Reserve tomorrow. Investors, meanwhile, focused on some notable insider trades.